Nigerian pharmacist and PhD researcher Chika Onochie’s doctoral research studying new ways to assess male infertility recently received a scholarship worth CAD$100,000, approximately US$70,260, to support his work on male reproductive health.
His research at McGill University focused on molecular biomarkers that could provide insights into sperm function beyond conventional semen analysis. it focuses on male infertility, sperm biology and redox signalling, areas that could help researchers better understand why some fertility problems are not fully captured by standard semen tests.
Conventional semen analysis typically evaluates measures such as sperm concentration, movement and morphology. Onochie’s work looks further, examining molecular signals that may provide additional information about how sperm function.
From Pharmacy in Nigeria to Reproductive-health Research in Canada
Onochie’s academic journey began at the University of Benin, where he studied Pharmacy between 2015 and 2021, earning a Bachelor of Pharmacy degree.
After completing his pharmacy training, he worked as a clinical pharmacist at Central Hospital, Benin City, from October 2021 to September 2022.
He subsequently moved into clinical research, working as a Clinical Trial Assistant with the International Research Center of Excellence at the Institute of Human Virology Nigeria in Abuja between October 2022 and August 2023.
That experience preceded his move to Canada, where he began his doctoral studies in Pharmacology at McGill University in 2023.
Onochie has since worked as a Doctoral Researcher at the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, where his research centres on male reproductive health.
Research Beyond the Conventional semen test
A central focus of Onochie’s research is the search for molecular biomarkers that could complement existing approaches to male fertility assessment.
Such biomarkers could potentially help researchers and clinicians distinguish between different causes of impaired sperm function and provide information that may not be apparent from semen parameters alone.
Conventional semen analysis assesses parameters such as sperm concentration, movement and morphology. While these measures remain important, molecular biomarkers could potentially provide further insight into the biological mechanisms affecting sperm performance.
Onochie’s work examines sperm biology and redox signalling, including the role of oxidative and antioxidant processes in sperm function. His research therefore sits at the intersection of pharmacology, molecular biology and reproductive health.
Onochie has also contributed to peer-reviewed research in the field, building an academic record around male reproductive health and sperm biology.
His work comes at a time when male factors are increasingly recognised as an important part of infertility assessment, rather than fertility being treated primarily as a female-health issue.
Building on Nigerian Training
Onochie’s path from pharmacy training in Nigeria to doctoral research in Canada highlights the role of international academic training in developing specialised scientific expertise.
His work at McGill combines his background in pharmaceutical sciences with molecular research into male reproductive health.
With the CAD$100,000 scholarship supporting his doctoral project, Onochie is continuing research aimed at expanding the tools available for understanding male fertility.
For him, the research is not simply about measuring the number or movement of sperm, but understanding the biological processes that determine whether sperm can perform their reproductive function.
That approach could contribute to a broader understanding of male infertility and, potentially, to more precise ways of assessing patients whose fertility challenges are not adequately explained by conventional semen analysis.
